Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Phase 2

Terminated

Conditions: Pancreatic Neoplasm
Pituitary Neoplasm
Nelson Syndrome
Ectopic ACTH Syndrome

Interventions: Drug: pasireotide LAR

First Posted Date: 2009-08-13

Last Posted Date: 2016-07-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 118

Registration Number: NCT00958841

Locations: 🇺🇸
Cedars Sinai Medical Center The Pituitary Center (3), Los Angeles, California, United States
🇺🇸
Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles, California, United States
🇺🇸
Mount Sinai School of Medicine Study Coordinator, New York, New York, United States

and more 4 locations

Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program

Phase 4

Terminated

Conditions: Renal Transplantation

Interventions: Drug: Basiliximab
Drug: Enteric Coated Mycophenolic Acid (MPA)
Drug: RAD001
Drug: Corticosteroids
Drug: Cyclosporin A (CsA)

First Posted Date: 2009-08-11

Last Posted Date: 2014-06-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 207

Registration Number: NCT00956293

Locations: 🇩🇪
Novartis Investigative Site, München, Germany

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Panobinostat (LBH589)
Drug: 5-Azacytidine

First Posted Date: 2009-07-27

Last Posted Date: 2020-08-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 113

Registration Number: NCT00946647

Locations: 🇺🇸
Georgia Health Sciences University Dept. of MCG, Augusta, Georgia, United States
🇺🇸
Goshen Center for Cancer Care IU Cancer Center, Indianapolis, Indiana, United States
🇺🇸
University of Kansas Hospital and Medical Center SC - Univ KS, Kansas City, Kansas, United States

and more 6 locations

Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: QMF149 Twisthaler®
Drug: Mometasone Twisthaler®

First Posted Date: 2009-07-20

Last Posted Date: 2012-08-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2283

Registration Number: NCT00941798

Locations: 🇺🇸
Novartis Investigative site, Philadelphia, Pennsylvania, United States
🇸🇰
Novartis Investigator Site, Vrable, Slovakia
🇰🇷
Novartis Investigative SIte, Seoul, Korea, Republic of

and more 1 locations

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

Phase 2

Completed

Conditions: Chronic Plaque-type Psoriasis

Interventions: Drug: AIN457A
Drug: AIN457
Drug: Placebo

First Posted Date: 2009-07-17

Last Posted Date: 2015-08-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 404

Registration Number: NCT00941031

Locations: 🇳🇴
Novartis Investigative Site, Ålesund, Norway

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Placebo
Drug: Deferasirox

First Posted Date: 2009-07-16

Last Posted Date: 2020-11-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 225

Registration Number: NCT00940602

Locations: 🇺🇸
Willis-Knighton Cancer Center Dept of Onc, Shreveport, Louisiana, United States
🇺🇸
Hackensack University Medical Center Department of Research, Hackensack, New Jersey, United States
🇺🇸
Rocky Mountain Cancer Centers RMCC, Greenwood Village, Colorado, United States

and more 9 locations

A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors

Phase 2

Completed

Conditions: Advanced Gastrointestinal Stromal Tumors

Interventions: Drug: Imatinib

First Posted Date: 2009-07-16

Last Posted Date: 2011-07-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 135

Registration Number: NCT00940563

Locations: 🇮🇹
Novartis Investigative Site, Verona, Italy

Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren/ Valsartan
Drug: Telmisartan/ Ramipril

First Posted Date: 2009-07-15

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 88

Registration Number: NCT00939588

Locations: 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAX576 in Asthma Patients

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: QAX576
Drug: Placebo

First Posted Date: 2009-07-15

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT00940160

Locations: 🇬🇧
Novartis Investigator Site, Manchester, United Kingdom

Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C

Phase 4

Completed

Conditions: Liver Transplantation
Hepatitis C

Interventions: Drug: cyclosporin (Neoral)
Drug: tacrolimus (Prograf)

First Posted Date: 2009-07-14

Last Posted Date: 2015-05-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 92

Registration Number: NCT00938860

Locations: 🇬🇧
Novartis Investigative Site, Birmingham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy